Business Wire

TA Announces Completion of Tender Offer for Nexus AG

Share

TA Associates (“TA” or the “Firm”), a leading global private equity firm, announced today that its holding company, Project Neptune BidCo GmbH, successfully completed its tender offer (the “Offer”) to acquire all outstanding ordinary shares and stock acquisition rights of Nexus AG (“Nexus”), a leading European software company in the e-health sector. This transaction, undertaken in partnership with the Management Board of Nexus, marks a significant milestone in Nexus’s journey, positioning the Company for continued growth and innovation away from a stock market environment.

The Offer, which commenced on November 11, 2024, for 70.00 Euro in cash per share, was completed as scheduled on January 3, 2025, at the end of the additional acceptance period. At the time of completion, the Offer was accepted for 16,402,668 Nexus shares, representing approximately 94.95% of all Nexus shares, including 26.9% which TA secured through irrevocable undertakings with key Nexus shareholders. All of such shares have been accepted for payment in accordance with the terms of the Offer, and TA expects to promptly pay for such shares.

Settlement of the Offer remains subject to customary regulatory conditions, including antitrust and foreign investment control clearances. Subject to the fulfillment of these conditions, settlement of the Offer is expected in Q1 2025, at which point TA intends to delist Nexus from the Frankfurt Stock Exchange, increasing its operational flexibility to focus on long-term growth initiatives.

“TA has followed Nexus's growth trajectory for many years and admired its leadership in the European e-health market,” said Stefan Dandl, Director at TA. “With its modern technology platform, expansive product portfolio and unwavering focus on customer satisfaction, we believe Nexus is well positioned to capitalize on the growing demand for digital healthcare solutions.”

By taking Nexus private, TA aims to empower the Company to further strengthen its customer offerings, pursue strategic acquisitions and invest significantly in research and development, particularly in areas such as cloud computing and AI-driven solutions.

“We're excited to partner with Ingo and the exceptional Nexus team to further advance healthcare software solutions that empower healthcare providers and improve patient outcomes,” added Birker Bahnsen, Managing Director at TA.

“Nexus has consistently delivered double-digit growth and strong financial performance,” said Dr. Ingo Behrendt, CEO of Nexus AG. “We believe our strategic partnership with TA will accelerate our ability to develop cutting-edge solutions that enhance the efficiency and quality of care for our customers. With access to significant new resources and greater flexibility to leverage industry tailwinds, we will continue driving value for healthcare providers who trust our platforms to power their digital transformation.”

“After careful consideration, The Supervisory Board and Management Board of Nexus AG unanimously concluded that this strategic partnership represents the best path forward for Nexus, its shareholders and customers,” shared Dr. Hans-Joachim König, Chairman of the Supervisory Board of Nexus AG. “We believe it creates immediate value for Nexus and are excited by the opportunities ahead.”

About TA Associates

TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. Further information on TA can be found at www.ta.com.

About Nexus AG

Nexus AG develops and distributes software solutions for the international healthcare market. With the clinical information system (Nexus / KIS) and the integrated diagnostic modules, we now have a uniquely broad and interoperable product range that can cover almost all functional requirements of hospitals, psychiatric clinics, rehabilitation and diagnostic centers within our own product families. Nexus AG employs around 2,030 people, owns sites in nine European countries and supports customers in further 71 countries, in some cases via certified dealers. Due to the continuously growing demand for Nexus products, we have been able to build up a large customer base in recent years and regularly achieve increasing sales and results. Further information on Nexus AG can be found at www.nexus-ehealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113838688/en/

Contacts

Media
Maggie Benoit
mbenoit@ta.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alphemy Capital appoints Barry Schachter as Head of Portfolio Risk Management14.1.2025 21:26:00 CET | Press Release

Alphemy Capital S.A. (“Alphemy Capital”), a leading digital asset and blockchain investment manager, has appointed Barry Schachter as Head of Portfolio Risk Management. Schachter formally joined the firm in January 2025 after nine months as its Risk Management Advisor, where he worked closely with the investment team in developing new tools and analytics to enhance Alphemy Capital’s existing risk management framework. Schachter brings more than 20 years’ experience in executive risk management roles at top hedge funds, including Caxton, SAC, Balyasny, and Moore. An investment industry veteran, he has been instrumental in designing, implementing, and leading risk management functions at multiple firms, for some of these as a member of the pre-launch team. “I am excited to have Barry at Alphemy Capital in this senior leadership role,” said Roman Khrushch, CEO of Alphemy Capital. “Barry’s truly unparalleled combination of experience and expertise strengthens our team in multiple ways.” Ma

Zayed Sustainability Prize Celebrates Innovators Driving Global Progress at 2025 Awards14.1.2025 21:15:00 CET | Press Release

Today, His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, recognised the 2025 winners of the Zayed Sustainability Prize. Celebrating the transformational impact of 11 pioneering organisations and high schools from across the world, the Prize reflects the UAE’s commitment to fostering scalable solutions to global challenges and empowering communities in their pursuit of sustainable prosperity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114367660/en/ Zayed Sustainability Prize celebrates innovators driving global progress at 2025 Awards (Photo: AETOSWire) In a Ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by 11 Heads of State, Ministers, and business leaders, H.H. Sheikh Mohamed bin Zayed awarded the winners for their remarkable achievements, encouraging continued innovation in every corner of the globe. H.H. Sheikh Mohamed bin Zayed said: “The UAE remains steadfast in its co

Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market14.1.2025 18:07:00 CET | Press Release

Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/ Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire) “Justin has bee

Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution14.1.2025 17:45:00 CET | Press Release

Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced general availability of its new DVB ReAccess solutions that serves as a uniquely powerful over-the-air (OTA) Conditional Access System (CAS). The solution also provides users with added peace of mind following the recent completion of Cartesian’s Farncombe Security® Audit. DVB ReAccess addresses a notable hurdle for one-way networks such as broadcast satellite providers that lack bidirectional handshakes to identify and authenticate client devices authorized to decrypt content. In one-way networks, the security of content relies almost exclusively on the resistance and resilience of the CAS, the most secure of which have a client software deeply anchored within the device’s hardware, leveraging a number of security features provided by the chipset. Consequently, once a CAS is integrated on a device, it’s typically very challe

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome14.1.2025 17:19:00 CET | Press Release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United States and Canada for Rett syndrome in adults and pediatric patients two years of age and older. “This application underscores our continued dedication to the Rett community, and our commitment to making a meaningful impact for people living with Rett syndrome and their caregivers in the EU, who currently have no approved treatment options specifically for this condition,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “We look forward to working with the EMA to address this unmet need in the hopes of potentiall

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye